47 related articles for article (PubMed ID: 29258115)
1. MiR-129-5p Sensitizes the Response of Her-2 Positive Breast Cancer to Trastuzumab by Reducing Rps6.
Lu X; Ma J; Chu J; Shao Q; Zhang Y; Lu G; Li J; Huang X; Li W; Li Y; Ling Y; Zhao T
Cell Physiol Biochem; 2017; 44(6):2346-2356. PubMed ID: 29258115
[TBL] [Abstract][Full Text] [Related]
2. miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2019 Feb; 26(1-2):1-10. PubMed ID: 29925897
[TBL] [Abstract][Full Text] [Related]
3. BCAR4 facilitates trastuzumab resistance and EMT in breast cancer via sponging miR-665 and interacting with YAP1.
Ye X; Liu Q; Qin X; Ma Y; Sheng Q; Wu X; Chen S; Huang L; Sun Y
FASEB J; 2024 Apr; 38(7):e23589. PubMed ID: 38572594
[TBL] [Abstract][Full Text] [Related]
4. Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer.
Duan N; Hua Y; Yan X; He Y; Zeng T; Gong J; Fu Z; Li W; Yin Y
Adv Sci (Weinh); 2024 May; 11(18):e2309424. PubMed ID: 38460162
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation.
Liang Z; Ahn J; Guo D; Votaw JR; Shim H
Pharm Res; 2013 Apr; 30(4):1008-16. PubMed ID: 23184229
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab: dreams, desperation and hope.
Shepard HM
Nat Rev Cancer; 2024 May; 24(5):287-288. PubMed ID: 38491271
[No Abstract] [Full Text] [Related]
7. Retraction Note: miR-182 regulates trastuzumab resistance by targeting MET in breast cancer cells.
Yue D; Qin X
Cancer Gene Ther; 2024 Jun; ():. PubMed ID: 38839893
[No Abstract] [Full Text] [Related]
8. NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in
Gambardella V; Gimeno-Valiente F; Tarazona N; Martinez-Ciarpaglini C; Roda D; Fleitas T; Tolosa P; Cejalvo JM; Huerta M; Roselló S; Castillo J; Cervantes A
Clin Cancer Res; 2019 Mar; 25(5):1639-1649. PubMed ID: 30504425
[TBL] [Abstract][Full Text] [Related]
9. miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review.
Vo TH; El-Sherbieny Abdelaal E; Jordan E; O'Donovan O; McNeela EA; Mehta JP; Rani S
Biochem Biophys Rep; 2024 Mar; 37():101588. PubMed ID: 38088952
[TBL] [Abstract][Full Text] [Related]
10. Landscape of NcRNAs involved in drug resistance of breast cancer.
Kang Y
Clin Transl Oncol; 2023 Jul; 25(7):1869-1892. PubMed ID: 37067729
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Risk Factors of Pyrrotinib in Second- and Third-Line Treatments for HER2-Positive Advanced Breast Cancer.
Wang X; Huang Y; Yang Z; Yang Y; Wei F; Yan M; Li F
Comput Math Methods Med; 2022; 2022():7864114. PubMed ID: 36164613
[TBL] [Abstract][Full Text] [Related]
12. Ribosomal Protein S6: A Potential Therapeutic Target against Cancer?
Yi YW; You KS; Park JS; Lee SG; Seong YS
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008473
[TBL] [Abstract][Full Text] [Related]
13. Traditional Chinese Medicine for adjuvant treatment of breast cancer: Taohong Siwu Decoction.
Jiang H; Li M; Du K; Ma C; Cheng Y; Wang S; Nie X; Fu C; He Y
Chin Med; 2021 Dec; 16(1):129. PubMed ID: 34857023
[TBL] [Abstract][Full Text] [Related]
14. Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study.
Yang H; Wang W
Am J Transl Res; 2021; 13(9):10863-10870. PubMed ID: 34650767
[TBL] [Abstract][Full Text] [Related]
15. Role of microRNA-129 in cancer and non-cancerous diseases (Review).
Deng B; Tang X; Wang Y
Exp Ther Med; 2021 Sep; 22(3):918. PubMed ID: 34335879
[TBL] [Abstract][Full Text] [Related]
16. BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.
Gebhardt K; Edemir B; Groß E; Nemetschke L; Kewitz-Hempel S; Moritz RKC; Sunderkötter C; Gerloff D
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34063443
[TBL] [Abstract][Full Text] [Related]
17. Interplay between p53 and non-coding RNAs in the regulation of EMT in breast cancer.
Parfenyev S; Singh A; Fedorova O; Daks A; Kulshreshtha R; Barlev NA
Cell Death Dis; 2021 Jan; 12(1):17. PubMed ID: 33414456
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of ribosomal protein S6 suppresses proliferation, migration, and invasion in epithelial ovarian cancer.
Yang X; Xu L; Yang YE; Xiong C; Yu J; Wang Y; Lin Y
J Ovarian Res; 2020 Aug; 13(1):100. PubMed ID: 32862831
[TBL] [Abstract][Full Text] [Related]
19. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1.
Liang L; Fu J; Wang S; Cen H; Zhang L; Mandukhail SR; Du L; Wu Q; Zhang P; Yu X
Acta Pharm Sin B; 2020 Jun; 10(6):1036-1046. PubMed ID: 32642410
[TBL] [Abstract][Full Text] [Related]
20. MiR-129-5p sensitization of lung cancer cells to etoposide-induced apoptosis by reducing YWHAB.
Xu C; Du Z; Ren S; Liang X; Li H
J Cancer; 2020; 11(4):858-866. PubMed ID: 31949489
[No Abstract] [Full Text] [Related]
[Next] [New Search]
